Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity

Abstract Introduction Skin involvement in patients with psoriatic arthritis (PsA) worsens the severity and burden of disease. Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist, was compared to placebo (PBO) in the SPIRIT-P1 (NCT01695239) and SPIRIT-P2 (NCT02349295) studies in patients wi...

Full description

Bibliographic Details
Main Authors: April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-05-01
Series:Dermatology and Therapy
Subjects:
ACR response
Biologic DMARDs
Body surface area
Disease activity
Ixekizumab
Psoriatic arthritis
Online Access:https://doi.org/10.1007/s13555-024-01188-y

Internet

https://doi.org/10.1007/s13555-024-01188-y

Similar Items